The survey of 502 employers by Accolade, a company that provides health-care programs for employers, and research firm Savanta said 43% of the employers it polled could cover GLP-1 drugs in 2024 compared to 25% that cover them now.

GLP-1s, short for glucagon-like peptide 1 agonists, are used to treat type 2 diabetes and weight loss.

Nearly all the companies that are covering GLP-1 drugs plan to keep covering them next year, according to the survey.

Marsha Marrullier
Sr Employee Benefits Consultant
Marshap@corporatebenefitsnetwork.com